StimCell Energetics (STME) launches research pact on eBalance microcurrent effects

Rhea-AI Filing Summary

StimCell Energetics Inc. reported that it has signed a service agreement with the St. Boniface Hospital Albrechtsen Research Centre. The collaboration will explore how the company’s proprietary eBalance® device affects mitochondrial function in cultured sensory neurons, aiming to further define the physiological action of the microcurrents generated by the device.

The update was shared through an informational news release furnished under a Regulation FD disclosure, meaning it is provided for information purposes and is not treated as a formally filed financial statement.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001493712 false 0001493712 2025-12-02 2025-12-02

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) December 2, 2025

STIMCELL ENERGETICS INC.

(Exact name of registrant as specified in its charter)

NV	000-54500	38-3939625
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
555 - 1130 Pender Street, West Vancouver, British Columbia		V6E 4A4
(Address of principal executive offices)		(Zip Code)
Registrant’s telephone number, including area code:		(844) 238-2692

820 – 1130 Pender Street, West

Vancouver, British Columbia V6E 4A4

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

1

ITEM 7.01REGULATION FD DISCLOSURE 

On December 2, 2025, StimCell Energetics Inc. (the “Company”) issued an informational news release (the “Release”) announcing the signing of a service agreement with the St. Boniface Hospital Albrechtsen Research Centre, to explore the effects of the Company’s proprietary eBalance® device on mitochondrial function in cultured sensory neurons to further define the physiological action of microcurrents. A copy of the Release is attached to this Current Report on Form 8-K as Exhibit 99.1.

The information furnished pursuant to Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, unless the Company specifically states that the information is to be considered “filed” under the Exchange Act or incorporates it by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act.

ITEM 9.01FINANCIAL STATEMENTS AND EXHIBITS. 

(d)Exhibits 

The following exhibits are provided with this Current Report:

Exhibit Number		Description of Exhibit
99.1		News release dated December 2, 2025

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

STIMCELL ENERGETICS INC.

Date: December 2, 2025

By: /s/ David Jeffs

David Jeffs,

Chief Executive Officer

3

FAQ

What did StimCell Energetics Inc. (STME) announce in this 8-K filing?

StimCell Energetics Inc. announced that it signed a service agreement with the St. Boniface Hospital Albrechtsen Research Centre to study its eBalance® device.

What is the focus of the new research collaboration for STME?

The collaboration will explore the effects of StimCell’s eBalance® device on mitochondrial function in cultured sensory neurons to better define how its microcurrents act physiologically.

How did StimCell Energetics Inc. disclose this agreement?

The company disclosed the agreement via an informational news release furnished under Item 7.01 Regulation FD Disclosure of a Form 8-K.

Does this STME 8-K include financial statements or earnings data?

No. The 8-K focuses on the research service agreement and attaches a news release as Exhibit 99.1; it does not provide financial statements or earnings data.

Is the news release in the STME 8-K considered filed for liability purposes?

The company states that the information furnished under Item 7.01 and Exhibit 99.1 is not deemed “filed” under Section 18 of the Exchange Act unless specifically stated otherwise.

What exhibit is included with this StimCell Energetics Inc. Form 8-K?

The filing includes Exhibit 99.1, described as a news release dated December 2, 2025.